Migraine attacks are associated with release of the Abstract calcitonin gene-related peptide (CGRP) from trigeminal nerves. BIBN 4096 BS is the first CGRP receptor antagonist tested in humans showing response rates similar to those reported for triptans, together with very good safety and tolerability profiles. The objective of the current study is to develop a population pharmacokinetic/pharmacodynamic model resembling the mechanism of action of BIBN 4096 BS, and to extract by model-based simulations dosage formulations and pharmacodynamic properties that can assist in the development of CGRP receptor antagonists. Methods: 126 patients with an acute moderate to severe migraine attack lasting not more than 6 hours were enrolled in this phase IIa study. BIBN 4096 BS was given as a single intravenous 10-minute infusion at different dose levels ranging from 0.25 to 10mg. Severity of headache was measured up to 24 hours. Patients who did not show pain relief by 2 hours were allowed to take rescue medication. Severity of headache and time to rescue medication measurements were fitted simultaneously using logistic regression and time-to-event analysis with nonlinear mixed-effect modelling software NONMEM version V. Results: Severity of headache and time to rescue medication were described as a function of the fraction of the CGRP receptors blocked by BIBN 4096 BS, and controlled by the second-and first-order rate constants representing the onset (kon) and offset (koff) of the anti-migraine effects. The model predicted a slow rate of offset of the anti-migraine effect (half-life of koff = 21 hours). The model developed described the data well and was validated properly. Discussion: A semi-mechanistic population pharmacokinetic/pharmacodynamic model has been developed for the anti-migraine effects of BIBN 4096 BS, characterised by the severity of headache and time to rescue medication. Simulations exploring the effect of the rate of absorption, bioavailability after an extravascular administration and the rate of activation/inactivation of the anti-migraine effect were performed. The rate of absorption seems to play a minor role; however, at least bioavailability fractions of 0.2-0.3 should be obtained. With regard to the kinetics of the anti-migraine effect, and to achieve a response rate of 60% at 2 hours, values of kon should be >0.081 mL/ng/h. At later times after administration higher values of koff are associated with faster offset of the response. The simulations showed that molecules with high kon and low koff values are the most promising.
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Background
ble. BIBN 4096 BS is a non-peptide CGRP receptor antagonist that based on in vitro and in vivo preclinical studies shows very high affinity and speciMigraine is a very incapacitating transient disficity for the human CGRP receptor. [7, 8] ease affecting 12% of the general population, with a
Only very recently clinical data have become pathogenesis that is still not completely underavailable. In a proof of concept study where BIBN stood.
[1] Nevertheless it is known that the release of 4096 BS was administered intravenously by a 10 the calcitonin gene-related peptide (CGRP) from minute infusion to patients with migraine attacks trigeminal nerves is associated with migraine atrated as moderate to severe, the investigators found tacks.
[2] CGRP is a potent dilator of brain and dura response rates similar to the efficacy rates reported vessels and therefore it plays an important role in for triptans, together with good safety and tolerabiliregulating blood flow to the brain and pain-sensitive ty profiles. [9] In addition, the pharmacokinetics of meninges, and can also cause degranulation and BIBN 4096 BS have been characterised by means of subsequent release of inflammatory agents from menon-compartmental and population pharmacokinetningeal mast cells. [3, 4] ic analyses. BIBN 4096 BS showed a linear predict-A decrease in CGRP levels at the brain area can able pharmacokinetic behaviour that was not mainly be elicited by several mechanisms, for example the affected by standard demographic characterisinhibition of the release of CGRP. This mechanism tics. [10, 11] of action is used by the triptans, which have affinity Based on the pharmacokinetic and pharmacologfor multiple serotonin receptors, thereby producing ical profiles of BIBN 4096 BS, sufficiently high rate vasoconstriction of cerebral vessels, but also of corboth of absorption and bioavailability after extravasonary vessels. [5, 6] Another alternative is to block the cular administration will be crucial for achieving binding between CGRP and its receptor, for which therapeutic plasma concentrations. To have a tool an antagonist of the CGRP receptor has to be availaallowing exploring in silico an important clinical end-point (i.e. response rate at 2 hours after drug administration) based on different absorption characteristics and/or receptor binding properties would be very useful. Therefore the aim of the current manuscript is to develop a population pharmacokinetic/pharmacodynamic model resembling as much as possible the mechanism of action of BIBN 4096 BS, and to extract by model-based simulations dosage formulations and pharmacodynamic properties that can assist in the development of compounds from the new class of CGRP receptor antagonists. This is particularly challenging in the present work because of the nature of the pharmacodynamic re-Patients with significant medical (i.e. coronary arsponse data (i.e. non-continuous and informative tery disease by history, renal failure) or psychiatric dropouts). [12] illness were not allowed to participate in the study. A summary of demographic data including migraine Methods history is given in table I.
After the first screening visit, patients were asked
Patients and Study Design to return to the clinic when they had an acute moderate to severe migraine attack lasting no more than 6 Information regarding patients and study design hours. After randomisation, BIBN 4096 BS was has been presented elsewhere.
[9,11] Briefly, 126 pagiven as a single intravenous 10 minute infusion at tients with a diagnosis of migraine (with or without doses of 0.25, 0.5, 1, 2.5, 5, or 10mg to 1, 4, 20, 32, aura) according to the criteria of the International 16, and 12 patients, respectively. Placebo (xylitol) Headache Society [13] of at least 1 year were enrolled was also intravenously infused in 10 minutes to 41 in this randomised, double-blind, placebo-conpatients. Dose selection was based on a group-setrolled, multi-centre phase IIa study after giving quential adaptive treatment-assignment design in written informed consent. The study was conducted order to identify the lowest dose of BIBN 4096 BS in accordance with the Declaration of Helsinki. Oththat is superior to placebo with a low number of er main inclusion criteria were a history of one to six patients and to minimise exposure of patients to migraine attacks per month for the preceding 6 non-efficacious doses. [14, 15] Groups of six patients months, an age at the onset of migraines of ≤50 years, and a current age between 18 and 65 years. were treated, with four patients receiving BIBN next group was decreased if at least three of the four patients in the BIBN 4096 BS group had a response; otherwise, the dose was increased.
Migraine headache was evaluated by the investigator using the Headache Severity Scale (3 = severe; 2 = moderate; 1 = mild; 0 = none) at baseline, 0.5, 1, 2, 4, and 24 hours after the start of the infusion. Patients remained in the clinic until at least 4 hours after the start of the infusion. The 24-hour measurement was recorded by telephone. Patients who did not show pain relief by 2 hours (reduction from headache severity scores of 3 or 2 to 1 or 0) after the start of the infusion were allowed to take rescue medication. Rescue medication was defined as any medication other than study drug, given to the patient for relief of headache pain or associated symptoms.
Blood samples (8mL) were taken from a forearm vein on the opposite site of the infusion site predose, 10, 30 minutes, 1, 2, and 4 hours after the start of the infusion. Plasma was obtained from centrifugation and stored at -20°C until analysis for BIBN 4096 BS concentrations with an accurate and sensitive analytical high-performance liquid chromatography method. [11] Pharmacodynamic Data A total of 641 headache severity scores were obtained during the study and used in the analysis. Figure 1 shows the distribution of the probabilities for each score by dosage group and measurement time. Severity of headache scores obtained at times >2 hours for those patients that took rescue medication were not included in the analysis. 504 measurements were recorded at times ≤2 hours, and 76 and 61 observations were obtained from patients that did not ask for rescue medication at 4 hours and 24 hours after administration, respectively. The distribution of the times of rescue medication. The 24-hour bar corresponds to individuals that did not take rescue medication during the study period (censored data). P = probability; t = time; T = time after t when rescue medication was taken.
ing the probability of remaining in the study (i.e. 4096 BS and two patients receiving placebo. Start-patients that did not take rescue medication) as a ing with the dose of 1.0mg, the dose for the next function of the administered dose of BIBN 4096 BS group was determined on the basis of the response and the distribution of times where rescue medicaobserved in the preceding group. The dose in the tion was taken.
Data Analysis
Results from the population pharmacokinetic analyses are presented as model parameter estimates together with their corresponding relative standard Data from headache severity scores and time to errors computed as the ratio between the standard rescue medication obtained from all the patients error and the model parameter estimate. involved in the study were fitted simultaneously under the population approach using the Laplacian
Drug-Receptor Interaction Model
likelihood estimation method implemented in the BIBN 4096 BS binds to the CGRP receptor nonlinear mixed-effect modelling software blocking the binding of endogenous CGRP. Data NONMEM version V. [16] Headache severity scores from figure 1 show that BIBN 4096 BS shows were considered as ordered categorical variables remaining effects at least 24 hours after administraand were fitted using logistic regression, and time to tion, a result that is compatible with a slow dissociarescue medication was a time-to-event response vation of the drug-receptor complex, and which is riable described by survival analysis. [17, 18] supported from receptor binding studies performed Once a model providing an adequate description in vitro.
[7] Figure 3 shows schematically the model of the data without the incorporation of covariates used to relate the time course of the drug in plasma was selected, patient characteristics listed in table I with severity of headache and time to rescue mediwere explored for significance using the generalised cation through the fraction of CGRP receptors that is additive model (GAM) approach implemented in blocked by BIBN 4096 BS (R*). Additionally, the the software Xpose version 3. [19, 20] The covariates effect compartment [21] and the indirect response initially selected during the GAM analysis are fur-models were also fitted to the data, [22] assuming that ther tested for significance in NONMEM using the the lack of direct relationship between drug in plasforward inclusion and backward elimination ap-ma and response is caused by a distribution process proach.
between the plasma and biophase, or that the drug acts by stimulating or inhibiting the factors controlModel selection was done based on a number of ling the synthesis and degradation processes of the criteria, such as the goodness-of-fit plots, precision response. of model parameter estimates, and the difference in Following the law of mass action the dynamics of the minimum value of the objective function (-2 R* are represented by equation 1: log[likelihood]; -2LL) provided by NONMEM. A difference of 6.63 points in -2LL between two nested models differing by one parameter was condt dR* = k on · C · R -k off · R* sidered significant at the 1% level.
(Eq. 1) where dR*/dt is the rate of change of R*, C corresponds to the predicted plasma concentrations of BIBN 4096 BS that were obtained from the pharmacokinetic model developed previously, [11] R is the concentration of unblocked receptors, and kon and koff represent the second-and first-order rate constants representing the onset and offset of the anti-migraine effect elicited through the respective amount of CGRP receptors blocked by BIBN 4096 BS. Setting the total concentration of CGRP receptors (RT) arbitrarily to 1, substituting R by 1 -R*, yields the expression (equation 2) used during model fitting: showing that the severity of headache is lower or equal to m (cumulative probability), given that the subjects did not take rescue medication [P(Y≤m|T≥t)]. n = the number of subjects at the beginning of the treatment; note that such number is decreased at times >2 hours because subjects took rescue medication. P = probability; t = time; T = time after t when rescue medication was taken; Y = observed score.
where PYij represents the probability of getting a score (Y)≤m (cumulative probability) in the ith indi- (Eq. 7) where lim refers to limit.
The hazard function has to be nonnegative, but (Eq. 5) apart from that restriction hz(t) can adopt any shape where fbaseline(m) describes the distribution of basewhich will be driven by the data. In the current line scores and has the form (equation 6):
analysis it has the form of equation 8:
where βk are the parameters defining the baseline (Eq. 8) probabilities. To account for a placebo effect where hz0, is the value of the hazard at baseline; (gplacebo), various time-dependent (maximum effect hzmax is the maximum decrease with respect to hz0 [Emax] type, or biexponential) [18] functions were that R* can elicit (0 ≤hzmax ≤1); hz50, is the value of tested. Drug effects were represented by a function R* that produces half of maximal reduction in hz0; k (h) of the fraction of CGRP receptors that is blocked is a parameter that allows to describe a time depenby BIBN 4096 BS. Four different models were dent decrease in hz. The model describes a decrease tested for h: the linear, Emax, sigmoidal Emax, and in hz(t) as R* and t increase. Denoting HZ(t) as the the power model. The logistic model predicts an cumulative hz(t) value, the probability of remaining increased probability of showing mild or no pain in the study [P(T>t)] at least to time t is given by the when R* increases.
survival function, S(t), where S(t) = e -HZ . Before Goodness-of-fit graphs were created showing the rescue medication was allowed S(t) was set to 1, but mean raw data and mean model predicted cumulathe hazard was allowed to accumulate. tive probabilities for each dose group and time of Goodness-of-fit plots include the nonparametric measurement. The posterior predictive check was Kaplan-Meier plot created with the raw data superused to further explore the descriptive capability of imposed by the model predicted probability of rethe selected model.
[23] Severity of headache scores maining in the study for each dose group. for 1000 datasets with the same characteristics of the original one were simulated using the selected Simulations model and its population model estimates. For the Model based computer simulations were pertwo dose groups with higher number of patients formed with the aim to aid in the design and further (placebo and 2.5mg) and for each of the simulated development of CGRP receptor antagonists. datasets P(Y≤1) at 2 hours after the start of the In the first case and taking into account that in administration of BIBN 4096 BS was computed and principle an extravascular formulation represents a the distributions were represented graphically tobetter choice than the intravenous administration, gether with the corresponding raw data probability.
using the mean population estimates obtained from
Model for Rescue Medication
the selected model, P(Y≤1) values at 2 hours after The hazard function [hz(t)] in the analysis of the administration were simulated for several combinarescue medication data is defined as the instantane-tions of rate of absorption (represented by the firstous probability of taking rescue medication at a order rate constant of absorption [ka]) and bioavai-lability values. ka values ranged from 0.34 to 6 h -1 ; blocked by BIBN 4096 BS was scaled linearly to values that correspond to times at which 90% of the describe drug effects on the severity of headache administered dose have been absorbed within 6 and response. The Emax, sigmoidal Emax, and power 0.5 hours, respectively. Bioavailability ranged from models did not elicited a significant decrease in 0.05 to 1.
-2LL (p > 0.05), and also the drug effect parameters were estimated with very poor precision. For the second case P(Y≤1) values at 2, 4, 6, and 8 hours after the start of administration were simuWith regard to time to rescue medication, the lated for several combinations of kon and koff. Val-model represented by equation 8 provided an estiues ranged between ± 5-fold of those estimated in mate of hzmax equal to 1 and the resulted value of the current analysis. In this simulation the -2LL was almost identical to a model where the pharmacokinetic behaviour of BIBN 4096 BS re-effects of R* were described with an exponential mained unchanged. model (equation 9): The results from the simulations were presented hz(t) = hz 0 · e -k R · R* · e -k · t in tri-dimensional plots to facilitate the interpreta-(Eq. 9) tion.
where kR is the first-order rate constant describing an exponential decrease in hz0 as a function of R*.
Results
Since this last model is simpler, it was the model The plasma concentration versus time profiles of finally selected. The term e -k • t , represents a de-BIBN 4096 BS could be best described by a three crease in the hazard with time and its incorporation compartmental model. BIBN 4096 BS shows dose in the model improved the fit significantly (p < independent pharmacokinetic behaviour between 0.001). the 0.25 and 10mg range, and none of the standard The effect compartment and the indirect response models performed worse than the receptor model described by equations 1 and 2. The values of -2LL corresponding the effect compartment, the indirect response, and the receptor models are 1592.774, 1609.785, and 1579.774, respectively.
Placebo effects were significant (p < 0.01) and its time course was best described with an Emax model using the time after drug administration as the predictor variable. The fraction of CGRP receptors nificance during the GAM approach. The results from the validation procedure shown in figure 6 confirm the model was supported by the data since there is a very good agreement between the model based simulated and observed P(Y≤1) values. The mean P(Y≤1) at 2 hours corresponding to the 1000 simulations are 0.29 and 0.6 for the 0 and 2.5mg dose groups, respectively, values that are very close to ones obtained from the observed data (0.27 and 0.65, respectively). Parameter estimates of the pharmacodynamic model are listed in table II. All parameters were estimated with acceptable precision. 
0.42 0.22 βx = set of baseline parameters of severity of headache; θSCL = parameter scaling the fraction of calcitonin gene-related peptide receptors blocked by BIBN 4096 BS (R*); ω 2 = population variance; hz0 = hazard value at baseline; k = first-order rate constant describing an exponential decrease in hz0 as a function of time after the start of administration; kon = second-order rate constant of activation of the anti-migraine effect; koff = first-order rate constant of inactivation of the anti-migraine effect; kR = first-order rate constant describing an exponential decrease in hz0 as a function of R*; PL50 = time at which the placebo effect is half of maximum; PLmax = maximum placebo effect. (f) Fraction of the subjects remaining in the study at least to time t [P(T>t), survival curve], in the placebo and drug-treated groups. P = probability; t = time; T = time after t when rescue medication was taken; Y = observed score.
the cumulative probability of achieving pain relief. of CGRP receptor antagonists by simulation techAs expected, the major impact of the effects is nology, the developed model should allow discrimiinduced by the drug blocking the receptor, especial-nating between pharmacokinetics and pharmacodyly at shorter times after drug administration. namics, and within pharmacodynamics, those Figures 7d and 7e correspond to the rescue medi-properties that are related to the drug and those cation model. At the time the rescue medication was belonging to the system. The model applied in the allowed, the value of the hazard decreased from 0.75 current study fulfills those requirements. Pharmato 0.2 in the simulated drug-treated group compared cokinetics were described with a standard three with placebo, due to the degree of the receptor compartment model with first-order elimination and blockade. The decrease with time in the hazard seen can be clearly differentiated from the time course of in the placebo group reflects the time effects quantidrug action.
[11] With regard to pharmacodynamics, fied by e -k • t . drug properties are represented by the receptor bindDiscussion ing model. The system related properties are represented by the baseline, placebo, and the parameters This report presents the application of population scaling R*. Nevertheless, taking into account the pharmacokinetic/pharmacodynamic modeling for absence of information at the receptor/biophase lev-BIBN 4096 BS, the first compound of the new class el, and the mechanistic models that have been develof CGRP receptor antagonists. Since the ultimate goal of this analysis is to assist in the development oped over the last years, the model presented here can be classified in the category of semi-mechanistic headache, or vice versa. Here, both types of remodels. [25] sponse data were fitted simultaneously by using the receptor binding model. Having a model describing The time course of pain response during drugthe probability of severity of headache is very usetreated migraine attacks has been described before ful, because it allows to compute [P(Y≤1)], reflectby using the population pharmacokinetic/pharmacoing the response rate at 2 hours ([P(Y≤1)]t = 2h) after dynamic approach. [26] Generally, time profiles simiadministration, an important efficacy endpoint for lar to those found after administration of BIBN 4096 the anti-migraine agents. The model for time to BS were also found for triptans and they were rescue medication is also interesting since the conmodeled using the effect compartment model. [21] cept of time-to-event analysis is receiving increasDelays between drug kinetics in plasma and reing attention in migraine research.
[30] sponse can be described with different models, which differ in the location of the rate-limiting step
Comparing model estimates at baseline for severwithin the cascade of events controlling the course ity of headache and time to rescue medication is of the response. [27] Results from our analysis suggest difficult; however, comparisons can be made for that the rate-limiting step is located at the receptor placebo and time effects and for the scaling paramelevel and consists on a slow rate of receptor inactiva-ters of the R* effects. For example, the estimate of tion. This finding is supported by data obtained in an PL50 of 2.6 hours indicates the time after adminisin vitro binding assay where a slow dissociation rate tration at which the placebo effect is half of maxiconstant with a value of 0.0018 min -1 was obtained mum; this finding is similar to the half-life estimate after binding of [7] Two decades hours]. In the case of R* effects and for a fraction of ago, during the modeling of the time course of the blocked CGRP receptors of 0.5, the induced absoeffects of the anti-migraine agent ergotamine, a slow rate of receptor inactivation (seen also in vitro) was also suggested as a possibility to explain the delay between kinetics in plasma and response.
[28] Two components contribute to pain relief in the model developed (placebo and drug effects), and only one to pain severity (CGRP). It is also possible that timedependent mechanisms such as development of central sensitisation play a significant role. However, due to lack of data the description of their kinetics and significance is not possible.
The data presented here include ordered categorical and survival data. Models describing the time course of headache severity scores and fitting the time to rescue medication as a function of the observable headache severity scores and time have been published in the past. [17, 18] More recently, a joint model has been proposed to deal with informative dropouts by describing the survival data as a function of the underlying unobserved data. [29] In the current analysis, time to rescue medication was not described as a function of the observable severity of lute changes in the value of the Logit and hazard be given by an extravascular administration and function were 1.5 and 0.95, respectively. assuming that the disposition is not affected. For bioavailabilities <0.5 a rapid absorption is required Ideally, as an anti-migraine medication should be (ka ~ 1-2 h -1 ) to achieve the maximum possible given via routes other than intravenous, the model response rate for a particular dose, otherwise the ka can be used to explore the influence of the absorption pharmacokinetics on the clinical outcome. Fig-has little impact. In contrast, the bioavailability is ure 8 shows the results of the simulated [P(Y≤1)]t = important to obtain the desired response rate value. 2h, based on different combinations of ka and Assuming that the total amount of drug in a particubioavailability values in case BIBN 4096 BS would lar dosage form can be, for example, 15mg, it ap-pears that a bioavailability between 0.2 and 0.4 of absorption seems to play a minor role; however, should at least be achieved to reach a response rate at least bioavailability fractions of 0.2-0.3 should be of 0.6 at 2 hours. When applying those results to obtained for extravascular dosage formulations. potential oral formulations, attention should be paid With regard to the receptor binding characteristics to the fact that migraine attacks might alter drug of new follow-up compounds, simulation shows that absorption increasing the variability in the molecules with fast kon and low koff are the most pharmacokinetic profiles and consequently affecting promising. the clinical response. [31] Simulations can be performed increasing the degree of intersubject varia
